Activities per year
Abstract
The vast majority of preclinical studies of HDAC inhibitors (HDAC-I) focus on the drug-target (cancer) cell interaction, whereas little attention is paid to the effects on non-target healthy cells, which could provide decisive information to eliminate potential cytotoxic compounds at a very early stage during drug development. In the current study we used cultures of primary rat hepatocytes as a read out system to select for the most potent HDAC-I in the group of structural analogues of an archetypal HDAC-I, namely Trichostatin A. This kind of approach allowed selecting compounds with high biological activity and with no apparent toxicity towards cultured hepatocytes.
Original language | English |
---|---|
Pages (from-to) | 338-346 |
Number of pages | 9 |
Journal | Invest New Drugs |
Volume | 27 |
Publication status | Published - 2009 |
Keywords
- HISTONE DEACETYLASE INHIBITORS
- HYDROXAMIC ACIDS
- DIFFERENTIATION
- APOPTOSIS
- CANCER
- primary hepatocytes
Fingerprint
Dive into the research topics of 'Screening of amide analogues of Trichostatin A in cultures of primary rat hepatocytes: search for potent and safe HDAC inhibitors'. Together they form a unique fingerprint.Activities
-
Epigen meeting
Jennifer Bolleyn (Speaker)
27 Feb 2014Activity: Talk or presentation › Talk or presentation at a workshop/seminar
-
Epigen meeting
Karin Vanderkerken (Participant)
27 Feb 2014Activity: Participating in or organising an event › Participation in workshop, seminar
-
Epigen meeting
Eva De Smedt (Participant)
27 Feb 2014Activity: Participating in or organising an event › Participation in workshop, seminar